BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 11784835)

  • 21. First generation antipsychotics switch with Risperidone in the treatment of chronic schizophrenic patients.
    Popović I; Ravanić D; Popović V; Vladejić S; Stanojević A; Stojanović M
    Psychiatr Danub; 2011 Dec; 23(4):384-8. PubMed ID: 22075740
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does risperidone improve verbal working memory in treatment-resistant schizophrenia?
    Green MF; Marshall BD; Wirshing WC; Ames D; Marder SR; McGurk S; Kern RS; Mintz J
    Am J Psychiatry; 1997 Jun; 154(6):799-804. PubMed ID: 9167507
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of aripiprazole versus risperidone on brain activation during planning and social-emotional evaluation in schizophrenia: A single-blind randomized exploratory study.
    Liemburg EJ; van Es F; Knegtering H; Aleman A
    Prog Neuropsychopharmacol Biol Psychiatry; 2017 Oct; 79(Pt B):112-119. PubMed ID: 28558941
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fasting insulin serum levels and psychopathology profiles in male schizophrenic inpatients treated with olanzapine or risperidone.
    Konarzewska B; Waszkiewicz N; Galińska B; Szulc A
    Neuro Endocrinol Lett; 2013; 34(4):322-8. PubMed ID: 23803867
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of risperidone versus olanzapine in patients with schizophrenia previously on chronic conventional antipsychotic therapy: a switch study.
    Wang X; Savage R; Borisov A; Rosenberg J; Woolwine B; Tucker M; May R; Feldman J; Nemeroff CB; Miller AH
    J Psychiatr Res; 2006 Oct; 40(7):669-76. PubMed ID: 16762371
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Suggested minimal effective dose of risperidone based on PET-measured D2 and 5-HT2A receptor occupancy in schizophrenic patients.
    Nyberg S; Eriksson B; Oxenstierna G; Halldin C; Farde L
    Am J Psychiatry; 1999 Jun; 156(6):869-75. PubMed ID: 10360125
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluordeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after remission and during linguistic-auditory activation.
    Parellada E; Lomena F; Font M; Pareto D; Gutierrez F; Simo M; Fernández-Egea E; Pavia J; Ros D; Bernardo M
    Nucl Med Commun; 2008 Oct; 29(10):894-900. PubMed ID: 18769307
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation between reduced in vivo benzodiazepine receptor binding and severity of psychotic symptoms in schizophrenia.
    Busatto GF; Pilowsky LS; Costa DC; Ell PJ; David AS; Lucey JV; Kerwin RW
    Am J Psychiatry; 1997 Jan; 154(1):56-63. PubMed ID: 8988959
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clozapine and risperidone in chronic schizophrenia: effects on symptoms, parkinsonian side effects, and neuroendocrine response.
    Breier AF; Malhotra AK; Su TP; Pinals DA; Elman I; Adler CM; Lafargue RT; Clifton A; Pickar D
    Am J Psychiatry; 1999 Feb; 156(2):294-8. PubMed ID: 9989566
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Symptoms in neuroleptic-naive, first-episode schizophrenia: response to risperidone.
    Kopala LC; Fredrikson D; Good KP; Honer WG
    Biol Psychiatry; 1996 Feb; 39(4):296-8. PubMed ID: 8645777
    [No Abstract]   [Full Text] [Related]  

  • 31. Frontal activity measured by near-infrared spectroscopy in patients taking different atypical antipsychotic drugs: A cross-sectional study.
    Kono S; Miura I; Oshima S; Hikita M; Wada A; Suzuki R; Niwa SI; Yabe H
    Psychiatry Res Neuroimaging; 2018 Mar; 273():42-45. PubMed ID: 29329742
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia.
    Karlsson P; Farde L; Halldin C; Sedvall G
    Am J Psychiatry; 2002 May; 159(5):761-7. PubMed ID: 11986129
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clozapine may partially compensate for task-related brain perfusion abnormalities in risperidone-resistant schizophrenia patients.
    Molina V; Tamayo P; Montes C; De Luxán A; Martin C; Rivas N; Sancho C; Domínguez-Gil A
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 May; 32(4):948-54. PubMed ID: 18262704
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of risperidone on cognition in patients with schizophrenia.
    Stip E; Lussier I
    Can J Psychiatry; 1996 Oct; 41(8 Suppl 2):S35-40. PubMed ID: 8899249
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dopamine D2 receptor occupancy by risperidone: implications for the timing and magnitude of clinical response.
    Catafau AM; Corripio I; Pérez V; Martin JC; Schotte A; Carrió I; Alvarez E
    Psychiatry Res; 2006 Dec; 148(2-3):175-83. PubMed ID: 17059881
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Toward a brain map of auditory hallucinations.
    Cleghorn JM; Franco S; Szechtman B; Kaplan RD; Szechtman H; Brown GM; Nahmias C; Garnett ES
    Am J Psychiatry; 1992 Aug; 149(8):1062-9. PubMed ID: 1353314
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Möller HJ; Riedel M; Jäger M; Wickelmaier F; Maier W; Kühn KU; Buchkremer G; Heuser I; Klosterkötter J; Gastpar M; Braus DF; Schlösser R; Schneider F; Ohmann C; Riesbeck M; Gaebel W
    Int J Neuropsychopharmacol; 2008 Nov; 11(7):985-97. PubMed ID: 18466670
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
    Schooler N; Rabinowitz J; Davidson M; Emsley R; Harvey PD; Kopala L; McGorry PD; Van Hove I; Eerdekens M; Swyzen W; De Smedt G;
    Am J Psychiatry; 2005 May; 162(5):947-53. PubMed ID: 15863797
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effects of risperidone and quetiapine on cognition in patients with schizophrenia and predominantly negative symptoms.
    Riedel M; Spellmann I; Strassnig M; Douhet A; Dehning S; Opgen-Rhein M; Valdevit R; Engel RR; Kleindienst N; Müller N; Möller HJ
    Eur Arch Psychiatry Clin Neurosci; 2007 Sep; 257(6):360-70. PubMed ID: 17629731
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Laterality and frontality of cerebral blood flow and metabolism in schizophrenia: relationship to symptom specificity.
    Gur RE; Resnick SM; Gur RC
    Psychiatry Res; 1989 Mar; 27(3):325-34. PubMed ID: 2785274
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.